Replies to post #77029 on Biotech Values

[tony111]

Xrymd,

Given your positive experience with Recothrom, do you think it will likely displace Bovine thrombin in two or three years? TIA.

[north40000]

ABT

You may want to find out the status of patent infringement suits brought by JNJ and Bayer[earlier] against ABT concerning
Humira. Both suits I think were[are] in the E.D.Texas. Still alive last I heard. I do not follow ABT.

Then,too, approval of JNJ's SYMPONI may have an effect.

[DewDiligence]

I agree—ABT is a solid core healthcare holding. Are there concerns? Of course; north40000 just mentioned two of them: litigation and competition from the recently approved Simponi.

However, I think these concerns are relatively minor in the overall scheme of things. ABT has some stellar franchises in both pharma and medical devices. Moreover, the decisions taken by ABT’s management have been right much more often than they’ve been wrong, and you can’t say this about very many companies in this arena.

p.s. Thanks for reminding me to update the ABT ‘Mini’ ReadMeFirst :- )